• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Ainos Inc.

    8/20/24 4:05:21 PM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AIMD alert in real time by email
    SC 13D/A 1 formsc13da.htm

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934
     

    (Amendment No. 8)*

     

    Ainos, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.01 per share

    (Title of Class of Securities)

     

    00902F303

    (CUSIP Number)

     

    Chun-Hsien Tsai

    Chief Executive Officer

    Ainos, Inc.

    14F., No. 61, Sec. 4, New Taipei Boulevard, Xinzhuang District

    New Taipei City 242, Taiwan F5

    886-37-581999

     

    (Name, Address and Telephone Number of Person Authorized to
    Receive Notices and Communications)

     

    August 15, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

    CUSIP No. 00902F303  

     

    1

    NAME OF REPORTING PERSON:

     

    Ainos Inc.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):
      (a) ☒
      (b) ☐
    3

    SEC USE ONLY:

     

                                                                                                    
    4

    SOURCE OF FUNDS (SEE INSTRUCTIONS):

     

    OO

    5

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e): ☐

     

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    7

    SOLE VOTING POWER:

     

    10,904,1841

    8

    SHARED VOTING POWER:

     

    0

    9

    SOLE DISPOSITIVE POWER:

     

    2,456,3192

    10

    SHARED DISPOSITIVE POWER:

     

    8,447,865

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

    2,456,3192

    12

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): ☐

     

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):

     

    17.97 2, 3

    14

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

    CO

     

     

    1, Includes (1) 2,456,319 shares of common stock, $0.01 par value, of Ainos, Inc., a Texas corporation (the “Issuer”), owned directly by Ainos Inc., a Cayman Islands company (“Ainos KY”), (ii) 538,868 shares pursuant to a Voting Agreement dated January 26, 2024 (the “2024 Voting Agreement”), by and among the Issuer, Ainos Inc., and Chun-Hsien Tsai, Ting Chuan Lee, Chun-Jung Tsai, and Chung-Yi Tsai (the “Tsai Group”); (iii) 96,920 shares of common stock pursuant to a Voting Agreement dated March 7, 2024 (the “2024 Voting Agreement II”) with Chih-Heng Lu; (iv) 2,312,077 shares pursuant to a Voting Agreement dated May 3, 2024 between Ainos KY and ASE Test, Inc. (“ASE Test” and the “ASE Voting Agreement”) (with the 2,312,077 ASE Test shares consisting of the following (a) 29,411 shares owned by ASE Test, (b) 282,666 shares issuable to ASE Test upon conversion of outstanding convertible notes of the Issuer and (c) 2,000,000 shares issuable to ASE Test upon conversion of a convertible note of the Issuer issuable within 60 days), and (v) 5,500,000 shares pursuant to a Voting Agreement dated August 15, 2024 between Ainos KY and Taiwan Carbon Nano Technology Corporation.

     

    2 Represents beneficial ownership of 2,456,319 shares of common stock of the Issuer, consisting of 2,456,319 shares owned directly by Ainos KY and excludes (i) 538,868 shares pursuant to the 2024 Voting Agreement; (ii) 96,920 shares of common stock pursuant to the 2024 Voting Agreement II; (iii) 2,312,077 shares pursuant to the ASE Voting Agreement as detailed in Note 1, and (iv) 5,500,000 shares pursuant to a Voting Agreement dated August 15, 2024 between Ainos KY and Taiwan Carbon Nano Technology Corporation.

     

    3 Based on the sum of (i) 7,663,022 shares of Common Stock outstanding as of August 2, 2024 as set forth in the Quarterly Report on Form 10-Q of the Issuer filed with the SEC on August 5, 2024, (ii) 382,384 shares of Common Stock issued to an institutional investor upon conversion of certain convertible notes on August 5, 2024, (iii) 5,500,000 shares of Common Stock issued to TCNT pursuant to the patent license agreement (the “License Agreement”) by and between the Issuer and TCNT, dated August 15, 2024, and (iv) 126,060 restricted stock units (“RSUs”) that vested on August 15, 2024 under the Ainos, Inc. 2023 Stock Incentive Plan with the underlying shares of the RSUs issued on August 16th.

     

     
     

     

    This Amendment No. 8 to Schedule 13D (“Amendment No. 8”) amends and supplements the Schedule 13D dated April 28, 2021 (the “Original Statement”), as amended and restated by Amendment No. 1 dated December 13, 2023, as amended by Amendment No. 2 dated March 8, 2022, as amended by Amendment No. 3 dated September 2, 2022, as amended by Amendment No. 4 dated August 15, 2023, as amended by Amendment No. 5 dated January 29, 2024, as amended by Amendment No. 6 dated March 11, 2024, as amended by Amendment 7 dated May 6, 2024 (the Original Statement, as so amended shall be known as the “Statement”), with respect to the (i) the common stock, par value $0.01 per share (the “Common Stock”), of the Issuer. Unless otherwise indicated, all capitalized terms used herein shall have the same meaning as set forth in the Statement.

     

    Except as set forth below, there are no changes to the information set forth in the Statement.

     

    Items 2, 3, 4, 5 and 6 of the Statement are hereby amended as follows:

     

    Item 2. Identity and Background

     

    (a-b) This Schedule is being filed by Ainos Inc., a Cayman Islands corporation (“Ainos KY”). The principal business and office address of Ainos KY is P. O. Box 31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1 - 1205 Cayman Islands.

     

    Ainos KY is controlled by Taiwan Carbon Nano Technology Corporation, a Taiwanese corporation (“TCNT” and together with the Issuer, the “Parties”). The principal business and office address of TCNT is 10F-2, No. 66, Shengyi 5th Rd., Zhubei City, Hsinchu County 30261, Taiwan (R.O.C.).

     

    (c) The principal business of Ainos KY is a holding company of the Issuer’s securities. The principal business of TCNT is the development of advanced materials for industrial and medical device applications.

     

    See Schedules A and B for information about the directors and executive officers of the Parties.

     

    (d-e) During the last five years, the reporting person and respective executive officers and directors, as applicable, have not (i) been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    Item 3. Source and Amount of Funds or Other Consideration

     

    Since the filing of Amendment No.7, Chun-Hsien Tsai, Ting Chuan Lee, Chun-Jung Tsai, and Chih-Heng Lu were awarded 26,100, 14,400, 16,200, and 6,000 restricted stock units (“RSUs”), respectively, under the Ainos, Inc. 2023 Stock Incentive Plan. Additionally, 1,920 RSUs will vest to Chih-Heng Lu under the Ainos, Inc. 2023 Stock Incentive Plan within 60 days of this Statement. Under the 2024 Voting Agreement and the 2024 Voting Agreement II, Ainos KY has the sole discretion to determine the vote of all the parties’ voting stock of the Issuer.

     

    Pursuant a patent license agreement by and between the Issuer and TCNT, the Issuer issued 5,500,000 shares of common stock to TCNT on August 15, 2024. On the same day, TCNT entered into a voting agreement with Ainos KY and, pursuant to such voting agreement, TCNT has agreed to vote all of the voting stock of the Company that is current owns or will acquire in the future in the manner determined by Ainos KY in its sole discretion.

     

    The information requested by this Item 3 is incorporated herein by reference to Item 5 hereof.

     

    Item 4. Purpose of Transaction

     

    Ainos KY acquired the Common stock in the Issuer for investment purposes.

     

    Except as disclosed herein, each of the Parties has no plans which relate to or would result in an event described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. However, each of the Parties may, from time to time, engage in discussions, whether initiated by the Parties or another party, concerning proposals for transactions or other arrangements that may relate to or, if consummated, result in an event described in Item 4 of Schedule 13D. Each of the Parties may review and evaluate their respective investments in the Issuer at any time, whether in light of the discussions described in the immediately preceding sentence or otherwise, which may give rise to plans or proposals that, if consummated, would result in one or more of the events described in Item 4 of Schedule 13D. Any such discussion or actions may consider various factors, including, without limitation, the Issuer’s business prospects and other developments concerning the Issuer, alternative investment opportunities, general economic conditions, financial and stock market conditions and any other facts and circumstances that may become known to the Parties regarding or related to the matters described in this Statement.

     

     
     

     

    Item 5. Interest in Securities of the Issuer

     

    Items 5 of the Statement are hereby amended and restated as follows:

     

    (a) - (b) The information requested by these paragraphs are incorporated herein by reference to the cover pages to this Amendment No. 8.

     

    (c) Since the most recent filing of Amendment No. 7 to Schedule 13D on May 6, 2024, the following transactions have occurred:

     

    (1) Effective August 15, 2024, Ainos KY and TCNT entered into a voting agreement with respect to the voting stock of the Issuer held by TCNT as described further in Item 6.

     

    (d) No other person is known to the Parties to have the right to receive or the power to direct the receipt of dividends or the proceeds from the sale of the Shares (other than their respective records owner).

     

    (e) Not applicable.

     

    Item 6. Contracts, Arrangements, Understandings or Relationships With Respect To Securities Of The Issuer

     

    Item 6 of the Statement is hereby amended and supplemented as follows:

     

    Pursuant a patent license agreement by and between the Issuer and TCNT, the Issuer issued 5,500,000 shares of common stock to TCNT on August 15, 2024. On the same day, TCNT entered into a voting agreement with Ainos KY and, pursuant to such voting agreement, TCNT has agreed to vote all of the voting stock of the Company that is current owns or will acquire in the future in the manner determined by Ainos KY in its sole discretion. The Voting Agreement may only be terminated if (i) Ainos KY directly holds less than 10% of the shares of the Issuer; or (ii) when Ainos KY directly holds shares which have less than 10% of the voting power in the Issuer. This voting agreement will cease to apply to a particular stockholder when the stockholder holds no shares in the Issuer; or when the stockholder ceases to be subject to the obligations under Section 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), if applicable.

     

    Other than the foregoing agreements and arrangements, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among Ainos KY or the Parties and any other person with respect to any securities of the Issuer, including, but not limited to transfer or voting of any of the securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

     

     
     

     

    Item 7. Material to be Filed as Exhibit

     

    Exhibit No.   Description
    1   Voting Agreement, dated August 15, 2024, between Ainos, Inc. and Taiwan Carbon Nano Technology Corporation

     

     
     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: August 20, 2024

     

      AINOS INC.
         
      By: /s/ Chun-Hsien Tsai
      Name: Chun-Hsien Tsai
      Title: Director and CEO

     

     
     

     

    SCHEDULE A

    Officers and Directors of Ainos KY

     

     

    Name   Principal Occupation (and name/address of employer if not one of the entities listed on this Schedule)   Principal Business Address   Interest in Issuer (in shared of Common Stock)
    Hung-Szu Tung   Director of Ainos KY   See Note 1.   None
    Chun-Hsien Tsai   Director of Ainos KY, Chairman and Chief Executive Officer of TCNT, and Chairman, President, and CEO of the Issuer   See Note 1.   397,5502
    Chun-Jung Tsai   Director of each of Ainos KY and TCNT and employee director of the Issuer   See Note 1.   88,3863
    Chih-Heng Lu   Director of Ainos KY and Director of Corporate Development of the Issuer   See Note 1.   96,920

     

    Note 1: The address of each individual is c/o Ainos, Inc., P. O. Box 31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1 - 1205 Cayman Islands and each individual is a citizen of Taiwan.

     

    Note 2: Chun-Hsien Tsai’s beneficially owns 302,319 (direct) shares and 95,231 (indirect) shares beneficially owned by his wife, Ting Chuan Lee, a director of the Issuer.

     

    Note 3: Chun-Jung Tsai beneficially owns 88,386 shares of Common Stock of the Issuer.

     

     
     

     

    SCHEDULE B

    Officers and Directors of TCNT

     

    Name   Principal Occupation (and name/address of employer if not one of the entities listed on this Schedule)   Principal Business Address   Interest in Issuer (in shared of Common Stock)
    Ting-Chuan Lee   Director of TCNT and employee director of the Issuer   See Note 1.   95,2312
    Chung-Yi Tsai   Director of TCNT and non-employee director of the Issuer   See Note 1.   52,9324
    Chun-Hsien Tsai   Director of Ainos KY, Chairman and Chief Executive Officer of TCNT, and Chairman, President, and CEO of the Issuer   See Note 1.   302,3192
    Chun-Jung Tsai   Director of each of Ainos KY and TCNT and employee director of the Issuer   See Note 1.   88,3863
    Ching-Ho Tsai   Director of TCNT   See Note 1.   None
    A-Wen Tsai Huang   Supervisor of TCNT   See Note 1.   None

     

    Note 1: The address of each individual is c/o 10F-2, No. 66, Shengyi 5th Rd., Zhubei City, Hsinchu County 30261, Taiwan (R.O.C.) and each individual is a citizen of Taiwan.

     

    Note 2: The combined beneficial ownership of Chun-Hsien Tsai and Ting Chuan Lee totals 397,550 shares. Chun-Hsien Tsai directly and beneficially owns 302,319 shares, and his wife, Ting Chuang Lee directly and beneficially owns 95,231 shares.

     

    Note 3: Chun-Jung Tsai beneficially owns 88,386 shares of Common Stock of the Issuer.

     

    Note 4: Chung Yi-Tsai beneficially owns 52,932 shares of Common Stock of the Issuer.

     

     

     

    Get the next $AIMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AIMD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AIMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Tsai Chun-Jung was granted 900,000 shares, increasing direct ownership by 170% to 1,427,900 units (SEC Form 4)

      4 - Ainos, Inc. (0001014763) (Issuer)

      4/9/25 4:15:35 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Lee Ting-Chuan was granted 900,000 shares, increasing direct ownership by 169% to 1,431,432 units (SEC Form 4)

      4 - Ainos, Inc. (0001014763) (Issuer)

      4/9/25 4:15:38 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO, PRESIDENT, CHAIRMAN Tsai Chun-Hsien was granted 900,000 shares, increasing direct ownership by 120% to 1,651,862 units (SEC Form 4)

      4 - Ainos, Inc. (0001014763) (Issuer)

      4/9/25 4:15:36 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AIMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Ainos Inc.

      SC 13D/A - Ainos, Inc. (0001014763) (Subject)

      11/27/24 6:08:44 AM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Ainos Inc.

      SC 13D - Ainos, Inc. (0001014763) (Subject)

      8/21/24 8:22:28 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Ainos Inc.

      SC 13D/A - Ainos, Inc. (0001014763) (Subject)

      8/20/24 4:05:21 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AIMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $AIMD
    Leadership Updates

    Live Leadership Updates

    See more

    $AIMD
    SEC Filings

    See more

    $AIMD
    Financials

    Live finance-specific insights

    See more
    • Water Tower Research Spotlights Ainos' AI Nose Programs and Strategic Milestones for 2025

      Report highlights greater visibility in AI Nose developments, including robotics, smart manufacturing, elderly care monitoring, and women's health testing SAN DIEGO, CA / ACCESS Newswire / January 21, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a pioneer of digiting scent and low-dose interferon therapeutics, today announced that Water Tower Research ("WTR") has published a report projecting increased visibility for the Company's transformative AI Nose programs. The report emphasizes anticipated progress for AI Nose across multiple sectors, including robotics, smart manufacturing, elderly care, and women's health.Key Highlights from the Report:AI Nose Technolog

      1/21/25 10:00:00 AM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ainos Granted 180-Day Extension by Nasdaq to Regain Compliance With Minimum Bid Price Rule

      SAN DIEGO, CA / ACCESS Newswire / January 17, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), today announced that it had received written notification (the "Written Notification") from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") that the Company is eligible for a 180-day extension to regain compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule").As previously reported, on July 15, 2024, the Company received a deficiency letter from the Nasdaq notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company's common stock has been below

      1/17/25 9:00:00 AM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ainos Unveils AI Nose for Robotics: Invites Global Robotics Companies to Join Forces in Shaping the Future of Smell-Enabled Robots

      Ainos invites robotics and humanoid companies to join Ainos Alliance and digitize smell SAN DIEGO, CA / ACCESSWIRE / January 13, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW), a pioneer of digitizing scent, proudly announces its revolutionary AI Nose for robotics application and invites robotics companies worldwide to join Ainos Alliance. This technology aims to equip robots with the ability to "smell," filling a long-standing gap in sensory capabilities. Powered by advanced artificial intelligence (AI) and micro-electromechanical systems (MEMS) gas sensors, AI Nose redefines how robots interact with the world, enabling transformative applications across industrial, healthcare, and everyday

      1/13/25 10:00:00 AM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ainos Unveils AI Nose for Robotics: Invites Global Robotics Companies to Join Forces in Shaping the Future of Smell-Enabled Robots

      Ainos invites robotics and humanoid companies to join Ainos Alliance and digitize smell SAN DIEGO, CA / ACCESSWIRE / January 13, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW), a pioneer of digitizing scent, proudly announces its revolutionary AI Nose for robotics application and invites robotics companies worldwide to join Ainos Alliance. This technology aims to equip robots with the ability to "smell," filling a long-standing gap in sensory capabilities. Powered by advanced artificial intelligence (AI) and micro-electromechanical systems (MEMS) gas sensors, AI Nose redefines how robots interact with the world, enabling transformative applications across industrial, healthcare, and everyday

      1/13/25 10:00:00 AM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14C filed by Ainos Inc.

      PRE 14C - Ainos, Inc. (0001014763) (Filer)

      5/19/25 4:15:23 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Ainos Inc.

      10-Q - Ainos, Inc. (0001014763) (Filer)

      5/14/25 4:05:51 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ainos Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Ainos, Inc. (0001014763) (Filer)

      5/12/25 9:01:07 AM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ainos Reports Third Quarter 2024 Financial Results

      Secured multi-regional patent assets, strengthening Ainos' AI Nose technology.Expanded VELDONA® patent portfolio with a new invention patent for treatments and preventions for coronavirus infections.Progressed clinical trials for VELDONA®, including new studies on Sjögren's syndrome and HIV-related oral warts. SAN DIEGO, CA / ACCESSWIRE / November 6, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced its financial results for the third quarter ended September 30, 2024.Chun-Hsien (Eddy) Tsai, Chairman of the Board, Preside

      11/6/24 4:30:00 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ainos Reports Second Quarter 2024 Financial Results

      Enrolling first subject for FCGS clinical study marks a solid start in shifting animal health emphasis to drug developmentsRobust financial runway for over 12 months following the prepayment of a senior secured convertible noteSAN DIEGO, CA / ACCESSWIRE / August 5, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW))) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and low-dose interferon therapeutics ("VELDONA®"), today announced its financial results for the second quarter ended June 30, 2024.Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "We've made meaningful progress

      8/5/24 4:15:00 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ainos Reports First Quarter 2024 Financial Results

      Strategic focus on VELDONA and AI-powered point-of-care testing continues during 2024US$9M growth capital secured in May strengthens financial position for executing growth strategy SAN DIEGO, CA / ACCESSWIRE / May 13, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW))) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of novel point-of-care testing ("POCT"), low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its financial results for the first quarter ended March 31, 2024.Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "In the first quarter, we successfully

      5/13/24 4:10:00 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care